Eli Lilly sold $176 million of the load loss drug Zepbound in precisely 4 weeks

Indianapolis-basically based mostly pharmaceutical company Eli Lilly sold $176 million of its fresh weight-loss drug Zepbound in precisely below a month, in step with the company’s fourth-quarter earnings legend released Tuesday. Zepbound, a GLP-1 weight reduction drug equal to Ozempic and Wegovy (both made by Novo Nordisk), launched in December.

HGTV’s Tarek El Moussa on how to flip homes for a income | Your Pockets

Request for Zepbound and Eli Lilly’s diabetes drug Mounjaro, which has also been historical off-imprint for weight reduction, has propelled the company’s income to $2.2 billion in the three months ended Dec. 31, up 13% from $1.9 billion in the the same duration the 12 months prior.

The company’s income in the fourth quarter soared 28% 12 months-over-12 months to $9.4 billion, from $7.3 billion.

Earnings per part came to $2.49, beating Wall Avenue expectations of $2.47, in step with a consensus estimate by Zacks Investment Research.

Provide constraints in 2024

Eli Lilly tasks that its 2024 income will attain between $40.4 billion and $41.6 billion. Its income in 2023 used to be $34 billion. The company also anticipates high demand for its weight reduction drug in the impending 12 months.

“The company continues to end on its manufacturing expansion agenda, nonetheless, given valid demand and the time required to bring manufacturing skill entirely on-line, the company expects that demand for incretins [GLP-1s] is possible to outpace supply in 2024,” the company acknowledged in a press release.

Eli Lilly stock has jumped merely about 4% to $732 one day of Tuesday morning procuring and selling. The company’s market cap for the time being stands at $670 billion, the best of any healthcare company globally.

Final week, head of healthcare sector approach for Norway’s sovereign wealth fund Gemma Sport predicted that Eli Lilly will be one of the most first healthcare companies to achieve a trillion greenback market cap. That distinctive membership is for the time being made up of tech and oil companies.

“Presumably in due direction we’ll be talking about Eli Lilly and Novo Nordisk as the field’s first trillion-greenback health care companies,” Sport acknowledged, at a press convention on Tuesday (Jan. 30).

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button